Low‐dose versus standard‐dose four‐factor prothrombin complex concentrate for factor‐Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage-Reference-Cited by-同舟云学术

Low‐dose versus standard‐dose four‐factor prothrombin complex concentrate for factor‐Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage

Published:2021-05-17 Issue:6 Volume:41 Page:501-507
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Cascone Ava E.¹^ORCID,Daley Mitchell J.²,Pan Neil²,Padilla‐Tolentino Eimeira²,Milling Truman J.³⁴

Affiliation:

1. Department of Pharmacy Boston Medical Center Boston Massachusetts USA

2. Department of Pharmacy Ascension Seton Austin Texas USA

3. Department of Surgery Dell Seton Medical Center at the University of Texas Austin Texas USA

4. Department of Neurology Dell Seton Medical Center at the University of Texas Austin Texas USA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2525

Reference27 articles.

1. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

2. Clinical review: prothrombin complex concentrates – evaluation of safety and thrombogenicity;Sorenson B;Crit Care,2011

3. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

4. Antithrombotic Therapy for VTE Disease

5. Antithrombotic Therapy for Atrial Fibrillation

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor–associated bleeding: A qualitative systematic review;American Journal of Health-System Pharmacy;2024-03-02

2. Reversal of pre-injury factor-Xa inhibitors with prothrombin complex concentrates in patients following traumatic brain injury;Clinical Neurology and Neurosurgery;2023-12

3. Response to the Letter by Spurling and Colleagues;Critical Care;2023-02-20

4. Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing;Research and Practice in Thrombosis and Haemostasis;2023-02

5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis;Critical Care;2022-06-16